[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635853":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":129,"collaborators":131,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":136,"sex":141,"minAge":142,"maxAge":12,"enrollmentInfo":143,"targetDuration":12,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"University Hospital, Antwerp","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"CT arm","NO_INTERVENTION","Treatment decision guided by radiographic evaluation following the standard of care of the treating hospital. (Control arm)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Liquid Biopsy arm","EXPERIMENTAL","Treatment decision guided by liquid biopsies. (intervention arm)",[18],"Other: Evaluation therapy through Liquid Biopsy",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"Evaluation therapy through Liquid Biopsy","The LB arm is the intervention group where the evaluation of therapy is guided by Liquid Biopsy results",[14],[25],{"name":26,"affiliation":5,"role":27},"Timon Vandamme","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":12,"email":33},"Sanne Wouters","CONTACT","003238212441","sanne.wouters@uza.be",{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},"Ayla Wyninckx","003232759745","ayla.wyninckx@uza.be",[39,53,63,72,81,91,101,110,120],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":12},"AZ Sint Maarten","RECRUITING","Mechelen","Antwerpen","2800","Belgium","BE",{"type":48,"coordinates":49},"Point",[50,51],4.47762,51.02574,{"lat":51,"lon":50},{"facility":54,"status":41,"city":55,"state":56,"zip":57,"country":45,"countryCode":46,"cosmosGeoPoint":58,"geoPoint":62,"contacts":12},"AZ Klina","Brasschaat","Antwerp","2930",{"type":48,"coordinates":59},[60,61],4.49182,51.2912,{"lat":61,"lon":60},{"facility":64,"status":41,"city":65,"state":56,"zip":66,"country":45,"countryCode":46,"cosmosGeoPoint":67,"geoPoint":71,"contacts":12},"University Hospital Antwerp","Edegem","2650",{"type":48,"coordinates":68},[69,70],4.44504,51.15662,{"lat":70,"lon":69},{"facility":73,"status":41,"city":74,"state":56,"zip":75,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":80,"contacts":12},"Sint-Augustinus (ZAS)","Wilrijk","2610",{"type":48,"coordinates":77},[78,79],4.39513,51.16734,{"lat":79,"lon":78},{"facility":82,"status":41,"city":83,"state":84,"zip":85,"country":45,"countryCode":46,"cosmosGeoPoint":86,"geoPoint":90,"contacts":12},"Grand Hopital de Charleroi","Charleroi","Henegouwen","6020",{"type":48,"coordinates":87},[88,89],4.44448,50.41136,{"lat":89,"lon":88},{"facility":92,"status":41,"city":93,"state":94,"zip":95,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":12},"AZ Maria Middelares, Ghent","Ghent","Oost-Vlaanderen","9000",{"type":48,"coordinates":97},[98,99],3.71667,51.05,{"lat":99,"lon":98},{"facility":102,"status":41,"city":103,"state":94,"zip":104,"country":45,"countryCode":46,"cosmosGeoPoint":105,"geoPoint":109,"contacts":12},"Vitaz","Sint-Niklaas","9100",{"type":48,"coordinates":106},[107,108],4.1437,51.16509,{"lat":108,"lon":107},{"facility":111,"status":41,"city":112,"state":113,"zip":114,"country":45,"countryCode":46,"cosmosGeoPoint":115,"geoPoint":119,"contacts":12},"AZ Sint Lucas, Brugge","Bruges","West-Vlaanderen","8000",{"type":48,"coordinates":116},[117,118],3.22424,51.20892,{"lat":118,"lon":117},{"facility":121,"status":41,"city":122,"state":113,"zip":123,"country":45,"countryCode":46,"cosmosGeoPoint":124,"geoPoint":128,"contacts":12},"AZ Groeninge, Kortrijk","Kortrijk","8500",{"type":48,"coordinates":125},[126,127],3.26487,50.82803,{"lat":127,"lon":126},{"type":130,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[132],{"name":133,"class":6},"Kom Op Tegen Kanker","100635853","phase-3-folicolor-trial-following-therapy-response-through-liquid-biopsy-in-metatstatic-colorectal-cancer-patients-100635853",false,"NCT07558083","FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","FOLICOLOR","Inclusion Criteria:\n\n* Man or woman ≥ 18 years of age at the time the informed consent is obtained\n* ECOG performance status of 0-2\n* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in subjects with unresectable metastatic (M1) disease\n* There should be at least 1 uni-dimensionally measurable (min. 10mm) using conventional crosssectional imaging techniques (CT or MRI scan). Lesion must not be chosen from a previously irradiated field, unlessnthere has been documented disease progression in that field after irradiation and prior to randomization. All sites of disease must be evaluated ≤ 28 days prior to randomization\n* Adequate hematology, renal, hepatic and coagulation function (at treating physician's discretion)\n* Adequate blood results for treatment (at treating physician's discretion)\n* Starting a first line treatment\n\nExclusion Criteria:\n\n* History of prior or concurrent central nervous system metastases\n* History of other malignancy, except:\n\nMalignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician.\n\nAdequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease.\n\nAdequately treated cervical carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer\n\n* Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)\n* Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) for the treatment of colorectal cancer ≤ 6 months prior to randomization with the following exceptions: Subjects may have received prior fluoropyrimidine therapy if administered solely for the purpose of radiosensitization for the adjuvant or neoadjuvant treatment of rectal cancer.\n* Radiotherapy ≤ 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities.","ALL","18 Years",{"count":144,"type":145},150,"ESTIMATED","INTERVENTIONAL",[148],"PHASE3","The FOLICOLOR trial aims to evaluate whether a liquid biopsy-guided follow-up strategy can improve outcomes in patients with unresectable, metastatic colorectal cancer (mCRC) receiving first-line systemic treatment. The approach uses NPY methylation-based circulating tumor DNA (ctDNA) analysis from blood samples to monitor treatment response and guide clinical decision-making. Eligible patients are adults diagnosed with unresectable, metastatic colorectal cancer who are starting first-line treatment. The primary goal is to demonstrate a clinically meaningful benefit, particularly in terms of quality of life (QoL) and reduction of treatment-related toxicity, by allowing earlier and more personalized therapeutic adjustments based on liquid biopsy findings.",[151],"Advanced Colorectal Cancer",[153,154,155],"NPY Methylation","Liquid Biopsy","advanced colorectal cancer patients","2026-04-22",{"date":158,"type":159},"2026-04-30","ACTUAL",{"date":161,"type":159},"2021-08-16",{"date":163,"type":145},"2031-08",{"name":5,"class":6},9]